Download MendeleyCrystal structure and biochemical studies of the trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis.
Ames, B.D., Nguyen, C., Bruegger, J., Smith, P., Xu, W., Ma, S., Wong, E., Wong, S., Xie, X., Li, J.W., Vederas, J.C., Tang, Y., Tsai, S.C.(2012) Proc Natl Acad Sci U S A 109: 11144-11149
- PubMed: 22733743 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1073/pnas.1113029109
- Primary Citation Related Structures:
3B6Z, 3B70 - PubMed Abstract:
Lovastatin is an important statin prescribed for the treatment and prevention of cardiovascular diseases. Biosynthesis of lovastatin uses an iterative type I polyketide synthase (PKS). LovC is a trans-acting enoyl reductase (ER) that specifically reduces three out of eight possible polyketide intermediates during lovastatin biosynthesis. Such trans-acting ERs have been reported across a variety of other fungal PKS enzymes as a strategy in nature to diversify polyketides. How LovC achieves such specificity is unknown. The 1.9-Å structure of LovC reveals that LovC possesses a medium-chain dehydrogenase/reductase (MDR) fold with a unique monomeric assembly. Two LovC cocrystal structures and enzymological studies help elucidate the molecular basis of LovC specificity, define stereochemistry, and identify active-site residues. Sequence alignment indicates a general applicability to trans-acting ERs of fungal PKSs, as well as their potential application to directing biosynthesis.
- Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA.
Organizational Affiliation:
